

Sneha Ramakrishna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1170578/publications.pdf>

Version: 2024-02-01

21
papers

2,481
citations

759233

12
h-index

839539

18
g-index

21
all docs

21
docs citations

21
times ranked

3116
citing authors

#	ARTICLE	IF	CITATIONS
1	CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. <i>Nature Medicine</i> , 2018, 24, 20-28.	30.7	1,030
2	GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. <i>Nature</i> , 2022, 603, 934-941.	27.8	339
3	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1419-1431.	30.7	273
4	Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas. <i>Cancer Immunology Research</i> , 2016, 4, 869-880.	3.4	258
5	Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22. <i>Molecular Therapy - Oncolytics</i> , 2018, 11, 127-137.	4.4	191
6	Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence. <i>Clinical Cancer Research</i> , 2019, 25, 5329-5341.	7.0	130
7	Delayed cancer diagnoses and high mortality in children during the COVID-19 pandemic. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28427.	1.5	61
8	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2321-2325.	1.4	51
9	Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2019, 134, 744-744.	1.4	42
10	Prospects and challenges for use of CAR T cell therapies in solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 503-516.	3.1	37
11	Novel CD19/CD22 Bicistronic Chimeric Antigen Receptors Outperform Single or Bivalent Cars in Eradicating CD19+CD22+, CD19-, and CD22- Pre-B Leukemia. <i>Blood</i> , 2017, 130, 810-810.	1.4	24
12	Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia. <i>Current Oncology Reports</i> , 2020, 22, 11.	4.0	13
13	Use of cardiac radiation therapy as bridging therapy to CAR-T for relapsed pediatric B-cell acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28870.	1.5	8
14	Abstract CT031: GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas. , 2021, , .		7
15	EPCT-14. GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG. <i>Neuro-Oncology</i> , 2021, 23, 149-i50.	1.2	6
16	CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 741-741.	1.4	4
17	Using single-cell analysis to predict CAR T cell outcomes. <i>Nature Medicine</i> , 2020, 26, 1813-1814.	30.7	2
18	Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report. , 2020, 8, e001073.		2

#	ARTICLE	IF	CITATIONS
19	Supercharging your CAR. Blood, 2020, 135, 593-594.	1.4	2
20	Abstract CT142: GD2.Ox40.CD28.z CAR T cell trial in neuroblastoma and osteosarcoma. Cancer Research, 2022, 82, CT142-CT142.	0.9	1
21	Use of Chimeric Antigen Receptor Modified T Cells With Extensive Leukemic Myocardial Involvement. JACC: CardioOncology, 2020, 2, 666-670.	4.0	0